Browse Companies

RYTHM, Inc., formerly Agrify Corporation, completed a significant strategic pivot in 2025 by exiting its legacy cannabis extraction business and rebranding to focus exclusively on licensing intellectual property for hemp-derived THC products. This transition drove a near doubling in revenue in 2025 compared to 2024, fueled primarily by brand licensing fees from established cannabis operators. However, ongoing federal regulatory uncertainty and licensee compliance risks temper near-term growth prospects. The company continues to absorb operating losses and negative free cash flow, reflecting costs associated with maintaining and defending its intellectual property portfolio amid a contested cannabis legal framework.

In its 2026 first quarter filing, Eastern Company demonstrated stable revenue recognition and maintained operational execution in its Engineered Solutions segment amid external pressures such as import-driven pricing competition and raw material cost volatility. The company’s business model centers on custom-engineered industrial components for commercial transportation and logistics, supported by a global manufacturing footprint including Asian subsidiaries that provide a cost advantage. While macroeconomic and geopolitical risks persist, Eastern leverages strong OEM relationships, engineering capabilities, and disciplined cost management to pursue organic growth and acquisitions. Liquidity remains robust with a current ratio above 3.5 and low net debt, providing flexibility to address near-term challenges and invest in growth.

In 2025, Fortitude Gold Corp shifted from contractor-based mining to an internally managed model at its Isabella Pearl Mine, a significant operational change that influenced cost structures and staffing. Though the year saw positive net income recovery after prior losses, operating cash flow turned sharply negative, impacted by working capital and investment dynamics. The company maintains a high customer concentration risk with one entity accounting for 94% of revenues, while recent joint venture activity signals exploration-led expansion ambitions within Nevada’s Walker Lane Mineral Belt. Capital allocation prioritizes dividends despite free cash flow deficits, reflecting cautious balance amid regulatory compliance complexities.

United Parks & Resorts reported a revenue beat in Q1 2026 while posting a net loss attributed to ongoing labor turnover, unionization activities, and operational inefficiencies. The company’s diversified portfolio of iconic brands combined with unique zoological assets sustains competitive advantage in a capital-intensive industry characterized by regulatory and geographic barriers. Growth initiatives focus on fresh attractions and cross-marketing within clustered parks, although significant debt and tight liquidity ratios remain key risk factors. Monitoring upcoming labor negotiations, capital expenditure execution, and debt management will be critical for assessing near-term resilience.

AnaptysBio recently completed a strategic spin-off that separated its biopharma development operations into First Tracks Biotherapeutics, leaving AnaptysBio as a lean royalty management entity. Its primary revenue source stems from royalties tied to GSK’s commercialization of Jemperli, making the company highly dependent on GSK’s execution and market performance. The business model pivots away from R&D towards intellectual property licensing and royalty collection. Key risks include reliance on collaborator success, ongoing litigation, and the inherent uncertainties in patent protection and enforcement. Near-term growth drivers hinge largely on sustained sales momentum of Jemperli and potential milestone payments. The company maintains strong liquidity with no reported debt, positioning it to manage operational expenses and strategic initiatives with a streamlined cost base.

Horizon Technology Finance Corp experienced significant volatility over recent years, transitioning from a steep net loss of $17.2 million in 2023 toward a much narrower loss of $2.7 million in 2025, accompanied by a remarkable operating cash flow recovery to $56.6 million in 2025. The company’s focused debt investments across technology-driven niche sectors like biotechnology, medical devices, and sustainable energy underpin its specialized moat and risk management framework. Currently undergoing a pivotal merger with Monroe Capital Corporation involving stock issuance and cash consideration, Horizon faces key risks including transaction completion uncertainty and post-merger integration challenges. Going forward, monitoring portfolio credit quality, dividend sustainability, and the closure of merger conditions will be essential.

In Q1 2026, Civeo Corp maintained stable revenues driven by multi-year take-or-pay contracts with key resource operators in Australia’s Bowen Basin and Canadian oil sands. The company’s integrated hospitality model, encompassing owned lodges and customer-managed accommodations, continues to underpin revenue predictability despite commodity sector cyclicality. Growth momentum centers on expanding mobile lodging assets and deepening service integration amid evolving customer needs. However, risks persist from commodity price volatility, regional concentration, and contract renewal challenges. The April 2026 credit facility extension supports financial flexibility for operational execution.

Quantum-Si Inc (QSI) continues to operate at significant losses as it integrates artificial intelligence and machine learning into its research and administrative workflows. Despite strong liquidity and a favorable current ratio, the company faces headwinds from evolving AI regulatory frameworks that may increase compliance costs or limit operational efficiency. Capital raising through an equity sales agreement supports ongoing cash burn, while near-term revenue growth lacks clear catalysts. Monitoring regulatory developments, AI implementation outcomes, and capital markets access will be critical to assessing any inflection in profitability or growth trajectory.

Arcturus Therapeutics Holdings Inc. has advanced its proprietary messenger RNA (mRNA) technology platforms—self-amplifying mRNA (STARR®) and lipid nanoparticle delivery (LUNAR®)—culminating in the world's first approved sa-mRNA COVID-19 vaccine, KOSTAIVE®, commercialized in Japan with regulatory approvals in Europe and the UK. The company is progressing a pipeline targeting rare genetic liver and respiratory diseases, including cystic fibrosis and ornithine transcarbamylase deficiency, through Phase 2 studies. Despite platform validation and a global manufacturing network, Arcturus faces regulatory delays in U.S. approvals and a substantial $430 million write-down related to its collaboration with CSL Seqirus amid changing COVID-19 market dynamics. Financial results for FY2025 show narrowing operating losses but persistent negative operating cash flow and free cash flow deficits, supported by strong liquidity.

In the first quarter of 2026, Hyster-Yale, Inc. reported key operational updates highlighting its ongoing integration of Nuvera Fuel Cells into its Americas materials handling segment, expanding its energy solutions offering. Despite a difficult macroeconomic backcloth affecting volume across segments, the firm continues to leverage its diversified product portfolio and extensive manufacturing footprint across Americas, EMEA, and Asia-Pacific to sustain market presence. Growth initiatives center on advancing energy solutions integration, geographic expansion, and enhanced aftermarket services, while risks persist from cyclical end-market demand fluctuations and financial covenant constraints linked to its capital structure.

Credo Technology Group Holding Ltd posted a $37.1 million operating income and $52.2 million net income in FY2025, marking a sharp turnaround from prior losses. The company’s partnership with TensorWave to support next-generation AMD AI clusters underpins new revenue opportunities. As of January 31, 2026, Credo held $1.22 billion in cash and equivalents with a current ratio exceeding 10x, positioning it well for continued investment. Capital expenditures rose sharply reflecting growth investments. While growth prospects appear favorable amid AI hardware demand, risks include geopolitical uncertainty and limited public disclosure on technology specifics.

ABVC BioPharma remains a clinical-stage biopharmaceutical entity primarily advancing seven drug candidates and one medical device licensed from BioLite, focusing on CNS, oncology, and retinal conditions. The latest quarter reflects continuing revenue limitations mainly from contract manufacturing services through its BioKey subsidiary. Despite strategic partnerships in Asia and patent protections, the company confronts liquidity pressure highlighted by a severely impaired current ratio and net losses. Regulatory approval uncertainties and the need to secure additional capital underscore significant risks as ABVC strives for successful pipeline commercialization and broader market entry.

In Q1 2026, Crexendo finalized a $5 million term loan and a $5 million revolving credit line with Wells Fargo to partly fund its $35 million acquisition of Estech Systems, signaling a strategic expansion of its UCaaS offerings. The company continues to generate subscription-based recurring revenue from its proprietary cloud telecommunications platform, which licenses concurrent sessions to optimize network costs for providers. Despite competitive pressures and regulatory risks, Crexendo’s broad feature set, scalability, and growing customer base position it well in the evolving unified communications market. Investor focus will center on integration execution, subscription growth metrics, and financial covenant compliance in the near term.

Angel Oak Mortgage REIT, Inc. (AOMR) has recovered from its significant losses in 2022, achieving a net income turnaround to $44 million in 2025 with a portfolio concentrated in credit-sensitive, newly-originated non-QM loans largely sourced through affiliated entities. The REIT’s vertical integration via Angel Oak Mortgage Lending gives it a competitive edge in sourcing and underwriting differentiated mortgage assets. However, AOMR’s aggressive use of leverage and reliance on short-term financing lines underscore risks related to liquidity, financing costs, and conflicts of interest within its external management framework. Future growth hinges on stable securitization markets, successful asset origination, and managing evolving regulatory landscapes.

In its latest quarter, Evolus extended its commercial traction with Jeuveau® and Evolysse™ products, delivering revenue that outpaced expectations despite ongoing net losses tied to marketing investment. The company operates under a cash-pay model focused on neurotoxin and dermal fillers sourced internationally, facing stiff competition from entrenched incumbents like AbbVie and Galderma. Regulatory complexities, partner reliance for product approvals, and international supply risks shape its operational landscape. Evolus seeks growth through expanding brand awareness, geographic reach, and product approvals while managing capital structure pressures with $49.8 million cash against $160 million debt as of Q1 2026.

In its 10-Q filing for Q1 2026, Superior Group of Companies, Inc. reported a swing to profitability supported by robust performance in its three business segments: Branded Products, Healthcare Apparel, and Contact Centers. The company’s multi-brand approach spanning customized uniform programs, healthcare-specific apparel, and outsourced call-center services underpins its diversified revenue streams. Despite competitive pressures and supply chain sensitivities, Superior leverages strong brand recognition and integrated service offerings to drive structural growth opportunities. Its well-capitalized balance sheet with a favorable current ratio supports operational stability amidst risks from tariffs and cyber threats.

Ascent Industries Co. reported an 8.9% sales increase in Q1 2026 driven by strategic R&D investments, a new Chemicals-as-a-Service model, and a recent acquisition expanding its product capabilities. However, the company recorded a net loss and negative adjusted EBITDA for the quarter, reflecting ongoing costs tied to its growth initiatives and macroeconomic headwinds. Ascent’s integrated service approach aims to deepen customer relationships and differentiate in a competitive specialty chemicals market but depends critically on sustained demand, pricing power, and raw material stability.

Advantage Solutions operates a comprehensive outsourced sales, marketing, and merchandising platform serving over 4,000 CPG manufacturers and retailers across 100,000+ North American retail locations. After peaking revenue in FY2023, the company faced modest declines and narrowed operating losses through FY2025 amid labor cost pressures and evolving retail dynamics. Focused on operational simplification, technology modernization, and debt refinancing, Advantage aims to strengthen core services and omni-commerce capabilities in a competitive environment marked by client consolidation and margin pressures.

NeuroPace reported Q1 2026 results showing continued revenue growth driven by increased adoption of its brain-responsive neurostimulation system for drug-resistant focal epilepsy. The RNS System remains differentiated by its ability to deliver personalized electrical stimulation guided by real-time brain data, enabling durable seizure reduction in a difficult-to-treat patient population. The company targets comprehensive epilepsy centers and community specialists but faces challenges from supply chain vulnerabilities, reimbursement complexities, and regulatory compliance demands. Ongoing label expansion efforts and AI-driven analytics underpin growth potential while commercial execution depends on navigating competitive treatment alternatives and market constraints.

CPS Technologies Corp, an advanced materials firm specializing in proprietary metal matrix composites (MMCs), has seen volatile financial results characterized by a turnaround from a sizeable net loss in 2024 to modest net profit in 2025, driven by its niche product portfolio serving aerospace, defense, and high-reliability industrial markets. The company’s growth prospects hinge on expanding MMC solutions into defense and commercial segments such as electric vehicles and telecommunications, leveraging SBIR/STTR-funded R&D programs and new product initiatives like AlMax alloys and HybridTech Armor®. However, CPS faces risks stemming from high customer concentration—three customers accounted for 64% of 2025 revenues—and supply chain dependencies exacerbated by vendor sole-sourcing requirements. With limited operating leverage evidenced by low returns on equity and negative free cash flow in 2025, operational execution including a planned facility relocation will be key factors to monitor.

Versant Media Group began independent public trading in early 2026 following its spin-off from Comcast. Historically embedded within Comcast’s Media segment, Versant’s pre-spin financials show a steady decline in linear distribution and advertising revenues over the past three years, driven by industry-wide subscriber erosion and rating drops. Although digital platform revenues grew modestly, they remain a smaller portion of the mix. Operating income and net income fell sharply in 2025 due to these trends and increased SG&A expenses largely tied to separation activities. The company now carries $3 billion in long-term debt incurred for separation-related payments and working capital needs. Capital allocation includes a new dividend policy and a $1 billion share repurchase authorization, signaling a focus on shareholder returns despite margin pressures. Key risks revolve around reduced scale post-spin, ongoing media industry headwinds, and integration challenges of acquired businesses.

Kadant Inc delivered an 18% year-over-year revenue increase in Q1 2026, supported by integration gains from recent acquisitions such as Babbini and Clyde Industries. The company's core business model centers on its Sustainable Industrial Processing® platform, leveraging three specialized segments to provide capital equipment and consumables that drive efficiency and sustainability in fiber, energy, and water usage across process industries. Kadant’s competitive moat rests on proprietary engineered systems and long-term customer relationships reinforced by sustainability trends. Growth is fueled by geographic expansion, acquisition synergies, and ongoing R&D innovation, although execution risk, economic cyclicality, and leverage constraints merit close monitoring.

B&G Foods, Inc. demonstrated a notable turnaround in operating income for fiscal 2026, jumping 154.8% year-over-year to $97.1 million. However, net losses persisted at $43.3 million despite improved operational performance. Cost pressures from seasonal raw material sourcing, elevated freight rates, and intense competition weigh on margins, while Walmart accounts for roughly a third of sales, exposing the firm to significant customer concentration risk. The company maintains a healthy liquidity position with a current ratio above 3x but carries substantial leverage that limits financial flexibility. Dividends continue amid free cash flow generation of approximately $70.7 million, though negative return on equity underscores ongoing profitability challenges.

Caris Life Sciences, Inc. reported Q1 2026 operational progress maintaining its leadership in precision oncology diagnostics driven by its MI Profile and Caris Assure platforms, integrating AI/ML at scale. The company is expanding capacity with new laboratory infrastructure and advancing predictive AI models for therapy selection in cancers such as glioblastoma and NSCLC. However, the complex regulatory landscape around LDTs and payer reimbursement uncertainties remain key risks to near-term growth. Caris’ extensive clinico-genomic data assets, proprietary technology, and FDA approvals support durable competitive advantages in a rapidly evolving precision medicine industry.

Accel Entertainment, Inc. reported meaningful gains in operating income and net income for fiscal year 2025, with operating income rising nearly 19% year-over-year and net income jumping by 46% [F1]. The company maintains a robust liquidity profile, highlighted by a current ratio above 2.6 and substantial cash reserves [F1]. A notable CEO succession was declared early in 2026, with newly appointed executives set to guide operational execution and strategic initiatives [S15]. Capital allocation has leaned toward consistent share repurchases in recent years [F1], supporting shareholder value alongside operational growth. Key risks include execution during leadership change and limited public insight into specific business drivers [S5].

Fuel Tech, Inc. has experienced significant volatility in revenue, culminating in a nearly 70% drop by fiscal year 2025. Despite the sharp decline, the company improved its operating income loss by roughly 22%, reflecting tighter cost control amid challenging market conditions. Operating cash flow turned positive and increased substantially in 2025 despite ongoing net losses, supported by strategic investments and a conservative capital structure. The introduction of targeted sales commission plans for senior management underscores a prioritization of top-line growth through enhanced customer engagement at its core product lines. Nonetheless, Fuel Tech faces persistent risks from regulatory headwinds and limited evidence of a durable competitive moat within the pollution control sector.

In 2025, AMBEV reported a slight decline in revenue contrasted by an increase in net income, reflecting disciplined cost control amidst challenging commodity prices and market softness. The company's extensive brand portfolio, exclusive licensing agreements, and integrated supply chain underpin its resilient market position. Capital allocation remains conservative yet shareholder-friendly, supported by solid cash flows and manageable debt maturities. Going forward, regulatory changes in tax benefits and commodity price volatility present both challenges and areas to monitor for sustained growth.

Enliven Therapeutics has concentrated its development efforts on ELVN-001, a clinical-stage candidate targeting chronic myeloid leukemia, resulting in no commercial products or revenues to date. The company’s historical and recent financials reflect rising net losses and negative cash flows, substantially funded by equity raises. While initial clinical data from the ENABLE trial supports progression toward pivotal studies, financial sustainability and regulatory challenges pose critical risks. Investors should watch for clinical milestones, capital raises, and regulatory feedback to evaluate future viability.

Darling Ingredients Inc. has expanded its revenue consistently while facing significant pressure on its operating and net income margins, driven by increased scale in sustainable natural ingredient production. The company's diversified segments across Feed, Food, and Fuel Ingredients leverage a broad global footprint and strategic joint ventures, notably with Valero Energy. However, rising input costs, commodity price volatility, and substantial indebtedness have compressed profits and challenged returns. Capital deployment favors reinvestment to support asset growth and joint ventures over immediate shareholder returns, underscoring the tension between sustaining expansion and managing financial leverage.

After several years of net losses, Cellebrite DI Ltd. returned to solid profitability in FY2025 with $78 million net income and demonstrated healthy top-line growth alongside substantial operating cash flow generation. The company's leadership in digital intelligence and forensic cybersecurity, underpinned by strong governance frameworks and tax advantages from its Israeli base, supports its ongoing competitive positioning. Prospects center on continued scaling within law enforcement and enterprise markets, though evolving cyber threats and foreign private issuer status remain pertinent risks. Capital management remains conservative with no recent dividend payments or share buybacks.

Century Aluminum reversed prior losses to record a 30.2% increase in operating income to $158.1 million in 2025, backed by its diversified production footprint and long-term power supply agreements. Despite the net income declining by 87.6% due to restatements related to joint venture accounting and material control weaknesses, operational cash flow surged by 852%, reflecting improved earnings quality. The company faces ongoing risks from electrical power price volatility and commodity cycles but is investing heavily in sustainability and restart projects while maintaining disciplined capital structure management.

Immunome Inc. announced positive topline results from its pivotal Phase 3 trial of varegacestat in desmoid tumors, with plans for NDA submission in Q2 2026. The company advances a diversified pipeline anchored by innovative ADC technology and novel payloads. Financials reflect ongoing strategic R&D investments with improving operating losses but significant cash burn. Upcoming clinical milestones and regulatory progress will be crucial as Immunome transitions toward potential commercialization.

Paysafe Ltd reported near-flat revenues at $1.7 billion in 2025 with operating income nearly halving, reflecting margin compression despite manageable cost controls. The company’s expansion of its R&D budget highlights a clear strategic bet on innovation, especially in cybersecurity and payment technology enhancements. While competitive and regulatory headwinds persist, Paysafe’s diversified Merchant Solutions and Digital Wallets segments benefit from seasonal tailwinds and global reach. Capital allocation through aggressive share repurchases complements a solid liquidity profile, though returns remain modest. Governance updates aim to strengthen oversight as the company pursues growth amid evolving payments industry dynamics.

Anheuser-Busch InBev SA/NV remains the world’s largest brewer by volume, with operations spanning developed and developing markets and a diversified portfolio of global, multi-country, and local brands. Its historical growth has been driven by strategic mergers and acquisitions that expanded scale and market presence. Revenue showed slight decline in 2025, impacted by currency translation and inflation accounting adjustments, while net income improved robustly. The company targets growth through premiumization, category expansion, new business initiatives, and digital innovation. Elevated but managed debt levels pose financial risk factors, balanced against substantial liquidity and ongoing capital return programs including dividends and buybacks.

CalciMedica, a clinical-stage biopharma company pioneering therapeutics targeting calcium release-activated calcium (CRAC) channels, has demonstrated a scientifically differentiated platform with Auxora leading multiple Phase 2 trials for inflammatory diseases. Despite its technological promise, the company continues to grapple with significant net losses and cash burn fueled by ongoing clinical development costs. Its capital structure, reliant on milestone-based debt tranches and equity offerings, underscores funding constraints that interplay tightly with clinical progress. Upcoming Phase 3 milestones and financing events warrant close attention to gauge sustainability on its path toward potential commercialization.

Evolution Global Acquisition Corp (EVOX) launched in mid-2025 as a special purpose acquisition company (SPAC) focused on raising capital through IPO and private placement warrants to finance a future business combination. Its historical performance reflects typical SPAC financials: significant organizational costs and no operating revenues, offset partially by interest income earned on trust account investments. Future growth is wholly contingent on successfully identifying and closing a combination with an operating company, which remains inherently uncertain. The company maintains a strong liquidity position with $240 million raised and placed in trust accounts invested in U.S. Treasury obligations, but operational expenses and redemption risks require prudent management of available working capital.